The University of Tennessee Research Foundation (UTRF) celebrated the researchers whose achievements made 2018 a record-breaking year at the annual Innovation Awards ceremonies, held December 4 at the University of Tennessee Health Science Center in Memphis and December 5 at The Foundry on the Fair Site in Knoxville. Researchers at UTHSC received patent plaques, startup… Read More
The Clinical Trials Network of Tennessee (CTN2) has been activated. Operating as a separate 501(c)(3) subsidiary of the University of Tennessee Research Foundation (UTRF), CTN2 was created to enable the University of Tennessee Health Science Center (UTHSC) clinical research faculty to design, solicit, and conduct robust statewide clinical trials with the overarching goal of providing… Read More
The University of Tennessee Research Foundation (UTRF) announced its 2017 Maturation Funding recipients on December 15, 2016, granting four University of Tennessee Health Science Center faculty inventors $15,000 each to further develop their technology and answer important commercialization questions. Each year UTRF awards grants through its annual Maturation Funding program which is designed to help… Read More
The University of Tennessee Health Science Center (UTHSC) has received a nearly $500,000 i6 Challenge Award from the United States Economic Development Administration (EDA) to establish a Proof-of-Concept Center at UTHSC in partnership with Memphis Bioworks Foundation. The award was announced recently by U.S. Secretary of Commerce Penny Pritzker as part of the EDA’s 2016… Read More
Four faculty members at the University of Tennessee Health Science Center have received grants for $15,000 each from the University of Tennessee Research Foundation Maturation Funding Program. The program is designed to assist UT researchers to advance technologies that have the capacity for commercial success. The four grant recipients are Hassan Almoazen, PhD; Vanessa Morales-Tirado,… Read More
GTx, Inc. today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, to inhibit tumor growth in… Read More
